Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children
Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children
AIM: To determine the efficacy of Lactobacillus reuteri DSM 17938 at a dose of 10(9) CFU for
 the prevention of nosocomial diarrhea.

 TRIAL DESIGN: Double-blind, placebo controlled RCT. INTERVENTION: L reuteri DSM 17938 in a
 daily dose of 10(9) CFU. PRIMARY OUTCOME: Nosocomial diarrhoea (3 or more loose or watery
 stools in a 24 h that will occur more than 72 h after admission).
Nosocomial diarrhea is a common problem in hospitalized children. Previously, it has been
 documented that the administration of L reuteri DSM 17938 at a dose of 10(8) colony forming
 units (CFU) compared with placebo had no effect on the overall incidence of nosocomial
 diarrhea (Wanke & Szajewska, J Pediatr 2012). Whether higher doses of L reuteri DSM 17938
 have such effects needs to be substantiated in further randomized trials.
Inclusion Criteria:

 -  Children aged 1-48 mo admitted to the hospital for reasons other than diarrhea

 -  Signed informed consent.

 Exclusion Criteria:

 -  Acute gastroenteritis within 3 days before admission

 -  Symptoms other than diarrhea suggesting gastroenteritis

 -  Use of probiotics within 7 days before admission

 -  Immunodeficiency disorders

 -  Breastfeeding >50%

 -  Underlying gastrointestinal tract disorder

 -  Malnutrition (weight/high <3pc)